Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Hikma Pharmaceuticals (LSE:HIK): FTSE 100 Healthcare Stock Faces Questions on Growth, Pricing and Product Mix

Hikma Pharmaceuticals Plc (LSE:HIK) is being assessed through its latest available company information, sector conditions and the next measurable catalysts. The focus for 15 October 2026 is on separating verified operating developments from unconfirmed intraday market claims.

Ankur Sharma | 15 October 2026

Why hVIVO (LSE:HVO) Expands Specialized Inoculation Infrastructure to Meet Global Biopharma Challenge Demand

hVIVO plc (LSE:HVO) has solidified its global market leadership in human challenge clinical trials, completing the operational expansion and commercial ramp-up of its state-of-the-art quarantine trial facility in Canary Wharf, London. Quoted on the AIM market of the London Stock Exchange, the specialist contract …

Divya Sood | 15 October 2026

Why IXICO (LSE:IXI) Focuses Neuroimaging Biomarker Discovery on Rare Neurological and Neurodegenerative Indications

IXICO plc (LSE:IXI) is executing a strategic operational recovery, deploying advanced artificial intelligence neuroimaging algorithms and digital biomarker solutions across global biopharmaceutical clinical trials. Quoted on the AIM market of the London Stock Exchange, the medical technology specialist provides automated brain MRI and PET …

Divya Sood | 15 October 2026

How Avacta Group (LSE:AVCT) Validates AVA6000 Clinical Safety Profiles Across Multi-Center Oncology Trials

Avacta Group plc (LSE:AVCT) has streamlined its corporate strategy to focus resources exclusively on advancing its clinical-stage targeted oncology therapeutics pipeline on the London Stock Exchange's AIM market. Following a successful share capital raise and the planned divestment of non-core diagnostic divisions, the clinical …

Divya Sood | 15 October 2026

What CRISM Therapeutics (LSE:CRTX) Discloses Regarding ChemoSeed Delivery Implants for Solid Oncology Tumours

CRISM Therapeutics Corporation (LSE:CRTX) is advancing the development of its proprietary localized chemotherapy delivery platform, seeking to transform therapeutic outcomes for patients suffering from inoperable or recurrent solid tumors. Quoted on the AIM market of the London Stock Exchange, the clinical-stage biotechnology enterprise specializes …

Divya Sood | 15 October 2026

Convatec Group (LSE:CTEC) non-executive director Jens Viebke buys 24,400 shares worth about £56,000

In a notification published on 14 October 2026, Convatec Group Plc (LSE:CTEC) reported a share purchase by Jens Viebke, one of its non-executive directors. The notification is marked as an initial notification, rather than an amendment to an earlier filing.

Ankur Sharma | 15 October 2026

Physiomics (LSE:PYC) wins £119,000 modelling contract and signs non-binding terms to explore dosing software deal

On 14 October 2026, Physiomics announced two separate developments. The first is a contract win worth £119,000 for model-informed drug development (MIDD) work, including pharmacokinetic/pharmacodynamic (PK/PD) modelling. The second is the signing of non-binding heads of terms with an unnamed third party to explore …

Ankur Sharma | 15 October 2026

Avacta Group (LSE:AVCT) to present AVA6000 salivary gland cancer PFS data and AVA6103 trial design at ESMO 2026

On 14 October 2026, Avacta Group said it will present two posters at the European Society for Medical Oncology (ESMO) 2026 Congress, which runs in Madrid from 23 to 27 October 2026.

Ankur Sharma | 15 October 2026

CelLBxHealth (LSE:CLBX) signs c.US$65,000 work order with established US pharma partner

On 14 October 2026, CelLBxHealth said it had signed a new Statement of Work (SOW) under an existing Master Services Agreement with a US-based pharmaceutical company. The customer was not named but was described as an "established" pharmaceutical partner, which indicates that this is …

Ankur Sharma | 15 October 2026

What Is Behind the Investor Interest in EDX Medical Group (LSE:EDX) After Its Arnold Clark Deal?

EDX Medical Group plc (LSE:EDX) is holding a live investor presentation via Investor Meet Company on Wednesday 14 October 2026 at 14:30 BST, open to existing and potential shareholders. The session is being presented by Professor Sir Chris Evans, Chief Scientific Officer. The Cambridge-based …

Ankur Sharma | 15 October 2026
Support

Hi! How can we help you today?

Loading…